Frequency and types of


Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
Aug 2021
Historique:
pubmed: 21 10 2020
medline: 11 8 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Mutations in the epidermal growth factor receptor ( Tumor specimens from Moroccan patients with NSCLC were collected from five pathology laboratories between November 2010 and December 2017 to determine frequency and types of A total of 334 patients were enrolled: 242 (72.5%) males and 92 females (27.5%). A total of 56.9% had a history of smoking. Our findings confirm the genetic heterogeneity of NSCLC worldwide, reporting frequency of

Sections du résumé

BACKGROUND BACKGROUND
Mutations in the epidermal growth factor receptor (
METHODS METHODS
Tumor specimens from Moroccan patients with NSCLC were collected from five pathology laboratories between November 2010 and December 2017 to determine frequency and types of
RESULTS RESULTS
A total of 334 patients were enrolled: 242 (72.5%) males and 92 females (27.5%). A total of 56.9% had a history of smoking.
CONCLUSION CONCLUSIONS
Our findings confirm the genetic heterogeneity of NSCLC worldwide, reporting frequency of

Identifiants

pubmed: 33079008
doi: 10.1177/0300891620964571
doi:

Substances chimiques

Biomarkers, Tumor 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-340

Auteurs

Mohamed Lemine Sow (M)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Hind El Yacoubi (H)

Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Badreddine Moukafih (B)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Salif Balde (S)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Gloria Akimana (G)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Salma Najem (S)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Siham El Khoyaali (S)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Halima Abahssain (H)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Aicha Chaibi (A)

Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Shah Zeb Khan (S)

Department of Clinical Oncology, BINOR Cancer Hospital, Bannu, Pakistan.

Dario Trapani (D)

Department of Oncology and Hematology, University of Milan.
Division of New Drug Development, European Institute of Oncology, Milan, Italy.

Asmae Benzekri (A)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Merieme Ghaouti (M)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Lamia Gamra (L)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Amina Mestari (A)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Fouad Kettani (F)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Younes Rahali (Y)

Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Hind Mrabti (H)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Ibrahim Elghissassi (I)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Hassan Errihani (H)

Department of Medical Oncology, National Institute of Oncology, Faculty of Medicine and Pharmacy, Mohamed V University, Rabat, Morocco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH